Halozyme Therapeutics (HALO) Misses Q4 EPS by 214c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $130.34 +1.34%
EPS Growth %: +32.6%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
COHR, ATS, SICP, More
EPS Growth %: +32.6%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.24), $2.14 worse than the analyst estimate of $1.90. Revenue for the quarter came in at $451.76 million versus the consensus estimate of $393.92 million.
GUIDANCE:
Halozyme Therapeutics sees FY2026 EPS of $7.75-$8.25, versus the consensus of $8.18. Halozyme Therapeutics sees FY2026 revenue of $1.71-1.81 billion, versus the consensus of $1.76 billion.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- Relay Therapeutics, Inc. (RLAY) Tops Q3 EPS by 3c
- Veeco Instruments (VECO) Misses Q3 EPS by 9c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
